Explore this year's advancements in gastroenterology biosimilars, highlighting key FDA approvals and market dynamics ...

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Hedged Equity Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the quarter, the market is ...

Samsung Bioepis’ ustekinumab biosimilar receives Japanese marketing approval: Incheon, Korea Wednesday, December 24, 2025, 15:00 Hrs [IST] Samsung Bioepis Co., Ltd., a biopharma ...

Both Novo Nordisk NVO and Amgen AMGN are large-cap, innovation-driven healthcare leaders with global scale, strong balance ...

Samsung Bioepis Co. Ltd. has announced the marketing approval of Ustekinumab BS Subcutaneous Injection 45mg Syringes 'NIPRO', ...

SEOUL, Dec. 23 (Yonhap) -- Samsung Bioepis Co., a biosimilar drug developer under Samsung Group, said Tuesday it has received ...

Samsung Bioepis Co., Ltd. today announced the marketing approval of Ustekinumab BS Subcutaneous Injection 45mg Syringes ...

South Korean biosimilars specialist Celltrion said the European medicines regulator has adopted a positive opinion for an autoinjector version of SteQeyma, its biosimilar to Stelara (ustekinumab).

Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a ...

Johnson & Johnson's portfolio reshaping should enhance margins and long-term growth prospects. Click here to read why JNJ ...

Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma (TM), a ...

Johnson & Johnson JNJ faces several challenges, like potential losses from expiring drug patents, ongoing legal battles related to its talc powder and broader macroeconomic uncertainties. Here, we ...